Skip to main content
. 2017 May 19;12(5):e0177736. doi: 10.1371/journal.pone.0177736

Fig 2. Cytotoxicity assays using murine macrophages and B16F10-gp75 tumour cells.

Fig 2

(A) Remaining B16F10-gp75 cells after a 24 hour incubation with macrophages and 2 μg/ml TA99 mAbs (different isotypes). (B) FACS analysis of co-cultures of DiO labelled murine macrophages (FL1) and DiI labelled B16F10-gp75 (FL2) tumour cells after 24 hours of treatment with 1 μg/ml mouse IgG2a or human IgG1 or IgG3 TA99 mAb. Macrophages, which have phagocytosed B16F10-gp75 tumour cells are encircled in FACS plots. (C) Percentage of remaining viable tumour cells and (D) increase in number of macrophages, which have phagocytosed B16F10-gp75 tumour cells after treatment of co-cultures with different concentrations of mAb. Percentages of tumour cells after culture with isotype antibodies were set at 100%. Double-positive macrophages were depicted relative to the co-cultures with isotype antibodies (set to 1), as described previously [4]. Mouse MG4 or human HEPC mAb were used as isotypes controls, which were set to 100%. *P<0.05, **P<0.01, ***p<0.001, ****p<0.0001.